Suppression of growth and transformation and induction of apoptosis by EGR-1

Cancer Gene Therapy

Volumn 5, Issue 1, 1998, Pages 3-28

  Liu, Chaoting ^a   Rangnekar, Vivek M ^b   Adamson, Eileen ^c   Mercola, Dan ^a,d  

^a SIDNEY KIMMEL CANCER CENTER   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c BURNHAM INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer; EGR 1; Sp1; Transformation; Transforming growth factor 1; WT1

Indexed keywords

DNA BINDING PROTEIN; EARLY GROWTH RESPONSE FACTOR 1; EGR1 PROTEIN, HUMAN; IMMEDIATE EARLY PROTEIN; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; ZINC FINGER PROTEIN;

ANIMAL; APOPTOSIS; CELL TRANSFORMATION; GENETICS; HUMAN; PHYSIOLOGY; REVIEW; TRANSACTIVATION;

ANIMALS; APOPTOSIS; CELL TRANSFORMATION, NEOPLASTIC; DNA-BINDING PROTEINS; EARLY GROWTH RESPONSE PROTEIN 1; HUMANS; IMMEDIATE-EARLY PROTEINS; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA; ZINC FINGERS;

EID: 0031602586     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (177)

1. Sukhatme VP, Cao X, Chang LC, et al. A zinc finger-encoding gene coregulated with c-fos during growth and differentiation, and after cellular depolarization. Cell. 1988;53:37-43.
2. Christy B, Nathans D. Functional serum response elements upstream of the growth factor-inducible gene Zif268. Mol Cell Biol. 1989;9:4889-4895.
3. Changelian PS, Feng P, King TC, Milbrandt J. Structure of the NGFI-A gene and detection of upstream sequences responsible for its transcriptional induction by nerve growth factor. Proc Natl Acad Sci USA. 1989;86: 377-381.
4. Varnum BC, Lim RW, Kujubu DA, et al. GM-CSF and tetradecanoyl phorbol acetate induce a distinct, restricted subset of primary-response TIS genes in both proliferating and terminally differentiated myeloid cells. Mol Cell Biol. 1989;9:3580-3583.
5. Cao X, Koski RA, Gashler A, et al. Identification and characterization of the Egr-1 gene product, a DNA-binding zinc finger protein induced by differentiation and growth signals. Mol Cell Biol. 1990;10:1931-1939.
6. Darland T, Samuels M, Edwards SA, Sukhatme VP, Adamson ED. Regulation of Egr-1 (Zfp-6) and c-fos expression in differentiating embryonal carcinoma cells. Oncogene. 1991;6:1367-1376.
7. Madden SL, Cook DM, Morris JF, Gashler A, Sukhatme VP, Rauscher III FJ. Transcriptional repression mediated by the WT1 Wilms tumor gene product. Science. 1991;253:1550-1553.
8. Sakamoto KM, Bardeleben C, Yates KE, Raines MA, Golde DW, Gasson JC. 5′ upstream sequence and genomic structure of the human primary response gene, EGR-1/TIS8. Oncogene. 1991;6:867-871.
9. Haber DA, and Buckler AJ. WT1: a novel tumor suppressor gene inactivated in Wilms' tumor. New Biol. 1992;4:97-106.
10. Sukhatme VP. The Egr transcription factor family: from signal transduction to kidney differentiation. Kidney Int. 1992;41:550-553.
11. Madden SL, Rauscher III FJ. Positive and negative regulation of transcription and cell growth mediated by the EGR family of zinc-finger gene products. Ann N Y Acad Sci. 1993;684:75-84.
12. Gashler AL, Sukhatme VP. EGR protein 1 (Egr-1): prototype of a zinc-finger family of transcription factors. Prog Nucleic Acid Res Mol Biol. 1995;50:191-224.
13. Lemaire P, Vesque C, Schmitt J, Stunnenberg H, Frank R, Charnay P. The serum-inducible mouse gene Krox-24 encodes a sequence-specific transcriptional activator. Mol Cell Biol. 1990;10:3456-3467.
14. Joseph LJ, Le Beau MM, Jamieson Jr GA, et al. Molecular cloning, sequencing, and mapping of EGR2, a human early growth response gene encoding a protein with "zinc-binding finger" structure [published erratum appears in Proc Natl Acad Sci USA. 86:515, (1989)]. Proc Natl Acad Sci USA., 1989;85:7164-7168.
15. Chavrier P, Vesque C, Galliot B, et al. The segmentspecific gene Krox-20 encodes a transcription factor with binding sites in the promoter region of the Hox-1.4 gene. EMBO J. 1990;9:1209-1218.
16. Christy B, Sanders LK, Lau LF, Copeland NG, Jenkins NA, Nathans D. An Id-related helix-loop-helix protein encoded by a growth factor-inducible gene. Proc Natl Acad Sci USA. 1991;88:1815-1819.
17. Crosby SD, Puetz JJ, Simburger KS, Fahrner TJ, Milbrandt J. The early response gene NGFI-C encodes a zinc finger transcriptional activator and is a member of the GCGGGGGCG (GSG) element-binding protein family. Mol Cell Biol. 1991;11:3835-3841.
18. Patwardhan S, Gashler A, Siegel MG, et al. EGR3, a novel member of the Egr family of genes encoding immediate-early transcription factors. Oncogene. 1991;6: 917-928.
19. Cao X, Mahendran R, Guy GR, Tan YH. Detection and characterization of cellular EGR-1 binding to its recognition site. J Biol Chem. 1993;268:16949-16957.
20. Pavletich NP, Pabo CO. Zinc finger-DNA recognition: crystal structure of a Zif268-DNA complex at 2. 1 A. Science. 1991;252:809-817.
21. Nakagama H, Heinrich G, Pelletier J, Housman DE. Sequence and structural requirements for high-affinity DNA binding by the WT1 gene product. Mol Cell Biol. 1995;15:1489-1498.
22. Swirnoff AH, Milbrandt J. DNA-binding specificity of NGFI-A and related zinc-finger transcription factors. Mol Cell Biol. 1995;15:2275-2287.
23. Wang Z-Y, Qiu Q-Q, Enger KT, Deuel TF. A second transcriptionally active DNA-binding site for the Wilms' tumor gene product, WT1. Proc Natl Acad Sci USA. 1993;90:8896-8900.
24. Wang Z-Y, Masaharu N, Qiu Q-Q, Takimoto Y, Deuel TF. An S1 nuclease-sensitive region in the first intron of human platelet-derived growth factor A-chain gene contains a negatively acting cell type-specific regulatory element. Nucl Acid Res 1994;22:457-464.
25. Russo MW, Matheny C, Milbrandt J. Transcriptional activity of the zinc-finger protein NGFI-A is influenced by its interaction with a cellular factor. Mol Cell Biol. 1993; 13:6858-6865.
26. Gashler AL, Swaminathan S, Sukhatme VP. A novel repression module, an extensive activation domain, and a bipartite nuclear localization signal defined in the immediate-early transcription factor Egr-1. Mol Cell Biol. 1993; 13:4556-4571.
27. Russo MW, Sevetson BR, Milbrandt J. Identification of NAB1, a repressor of NGFI-A- and Krox20-mediated transcription. Proc Natl Acad Sci USA. 1995;92:6873-6877.
28. Svaren J, Sevetson BR, Apel ED, Zimonjic DB, Popescu NC, Milbrandt J. NAB2, a corepressor of NGFI-A (Egr-1) and Krox20, is induced by proliferative and differentiative stimuli. Mol Cell Biol. 1996;16:3545-3553.
29. 1 transition in cultured cells. EMBO J. 1988;7:29-35.
30. Mack KJ, Yi SD, Chang S, Millan N, Mack P. NGFI-C expression is affected by physiological stimulation and seizure in the somatosensory cortex. Brain Res Mol Brain Res. 1995;29:140-146.
31. Watson MA, Milbrandt J. The NGFI-B gene, a transcriptionally inducible member of the steroid receptor gene superfamily: genomic structure and expression in rat brain after seizure induction. Mol Cell Biol 1989;9:4213-4219.
32. Galéra P, Musso M, Ducy P, Karsenty G. c-Krox, a transcriptional regulator of type I collagen gene expression, is preferentially expressed in skin. Proc Natl Acad Sci USA. 1994;91:9372-9376.
33. Call KM, Glaser T, Ito CY, et al. Isolation and characterization of a zinc-finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell. 1990;60:509-520.
34. Briggs MR, Kadonaga JT, Bell SP, Tjian R. Purification and biochemical characterization of the promoter specific transcription factor, Sp1. Science. 1986;234:47-52.
35. Kadonaga JT, Carner KR, Masiarz FR, Tjian R. Isolation of cDNA encoding transcription factor Sp1 and functional analysis of the DNA binding domain. Cell. 1987; 51:1079-1090.
36. Denny P, Ashworth A. A zinc finger protein-encoding gene expressed in the post-meiotic phase of. spermatogenesis. Gene. 1991;106:221-227.
37. Kingsley C, Winoto A. Cloning of GT box-binding proteins: a novel Sp1 multigene family regulating T-cell receptor gene expression. Mol Cell Biol. 1992; 12:4251-4261.
38. Imataka H, Sogawa K, Yasumoto K, et al. Two regulatory proteins that bind to the basic transcription element (BTE), a GC box sequence in the promoter region of the rat P-4501A1 gene. EMBO J. 1992;11:3663-3671.
39. Sogawa K, Imataka H, Yamasaki Y, Kusume H, Abe H, Fujii-Kuriyama Y. cDNA cloning and transcriptional properties of a novel GC box-binding protein, BTEB2. Nucleic Acids Res. 1993;21:1527-1532.
40. Wimmer EA, Jackle H, Pfeifle C, Cohen SM. A Drosophila homologue of human Sp1 is a head-specific segmentation gene. Nature. 1993;366:690-694.
41. Bronner G, Chu-LaGraff Q, Doe CQ, et al. Sp1/Egr-1-like zinc-finger protein required for endoderm specification and germ-layer formation in Drosophila. Nature. 1994;369:664-668.
42. Blok LJ, Grossmann ME, Perry JE, Tindall DJ. Characterization of an early growth response gene, which encodes a zinc-finger transcription factor, potentially involved in cell cycle regulation. Mol Endocrinol. 1995;9: 1610-1620.
43. Schneider-Maunoury S, Topiko P, Seitanidou T, et al. Disruption of krox-20 results in alteration of rhombomeres 3 and 5 in the developing hindbrain. Cell. 1993;75:1199-1214.
44. Topilko P, Schneider-Maunoury S, Levi G, et al. Krox-20 controls myelination in the peripheral nervous system. Nature. 1994;371:796-799.
45. Honkaniemi J, Sagar SM, Pyykonen I, Hicks KJ, Sharp FR. Focal brain injury induces multiple immediate early genes encoding zinc-finger transcription factors. Brain Res Mol Brain Res. 1995;28:157-163.
46. Honkaniemi J, Kononen J, Kainu T, Pyykonen I, Pelto-Huikko M. Induction of multiple immediate early genes in rat hypothalamic paraventricular nucleus after stress. Brain Res Mol Brain Res. 1994;25:234-241.
47. Rauscher III FJ. The WT1 Wilms tumor gene product: a developmentally regulated transcription factor in the kidney that functions as a tumor suppressor. FASEB J. 1993;7:896-903.
48. Cip1. Nature. 1995;375:159-161.
49. Reddy JC, Morris JC, Wang J, et al. WT1-mediated transcriptional activation is inhibited by dominant negative mutant proteins. J Biol Chem. 1995;270:10878-84.
50. Hewitt SM, Fraizer GC, Wu Y-J, Rauscher III FJ, Saunders GF. Differential function of Wilms' tumor gene WT1 splice isoforms in transcriptional regulation. J Biol Chem. 1996;271:8588-8592.
51. Menke AL, Riteco N, van Ham RC, et al. Wilms' tumor 1 splice variants have opposite effects on the tumorigenicity of adenovirus-transformed baby-rat kidney cells. Oncogene. 1996;12:537-546.
52. Konig A, Jacubicska S, Wieacker P, Shlösser HW, Gessler M. Further evidence that imbalance of WT1 isoforms may be involved in Denys-Drash syndrome. Hum Mol Genet 1993;2:1967-1968.
53. Bruening W, Gross P, Sato T, et al. Analysis of the 11p13 Wilms' tumor suppressor gene (WT1) in ovarian tumors. Cancer Invest. 1993;11:393-399.
54. Johnstone RW, See RH, Sells SF, et al. A novel repressor, par-4, modulates transcription and growth suppression functions of the Wilms' tumor suppressor WT1. Mol Cell Biol. 1996;16:6945-56.
55. Sells S, Han S-S, Muthukkumar S, et al. Expression and function of the leucine zipper protein par-4 in apoptosis. Mol Cell Biol. 1997;17:3823-3832.
56. Kharbanda S, Nakamura T, Stone R, et al. Expression of the early growth response 1 and 2 zinc finger genes during induction of monocytic differentiation. J Clin Invest. 1991; 88:571-577.
57. Nguyen HQ, Hoffman-Liebermann B, Liebermann DA. The zinc-finger transcription factor Egr-1 is essential for and restricts differentiation along the macrophage lineage Cell. 1993;72:197-209.
58. Krishnaraju K, Nguyen HQ, Liebermann DA, Hoffman B. The zinc-finger transcription factor Egr-1 potentiates macrophage differentiation of hematopoietic cells. Mol Cell Biol. 1995;15:5499-5507.
59. Lee SL, Tourtellotte LC, Wesselschmidt RL, Milbrandt J. Growth and differentiation proceeds normally in cells deficient in the immediate early gene NGFI-A. J Biol Chem. 1995:270:9971-9977.
60. Shao H, Kono DH, Chen LY, Rubin EM, Kaye J. Induction of the early growth response (Egr) family of transcription factors during thymic selection. J Exp Med. 1997; 185:731-44.
61. Lee SL, Sadovsky A, Swirnoff AH, et al. Luteinizing hormone deficiency and female infertility in mice lacking the transcription factor NGFI-A (Egr-1). Science. 1996; 273:1219-1221.
62. 1 transition of the cell cycle. Mol Cell Biol. 1994;14:5242-5248.
63. Kinane TB, Finder JD, Kawashima A, et al. LLC-PK1 cell growth is repressed by WT1 inhibition of G-protein alpha i-2 protooncogene transcription. J Biol Chem. 1995; 270:30760-30764.
64. Kinane TB, Finder JD, Kawashima A, et al. Growth of LLC-PK1 renal cells is mediated by EGR-1 up-regulation of G protein alpha i-2 protooncogene transcription J Biol Chem. 1994;269:27503-27509.
65. Muthukkumar S, Nair P, Sells SF, et al. Role of EGR-1 in thapsigargin-inducible apoptosis in the melanoma cell line A375-C6. Mol Cell Biol. 1995;15:6262-6272.
66. Rupprecht HD, Hofer G, Sterzel RB, Schocklmann HO. Egr-1 transcription factor regulates the growth of glomerular mesangium cells. Med Klin. 1997;92:68-73.
67. Pasumarthi KB, Jin Y, Cattini PA. Cloning of the rat fibroblast growth factor-2 promoter region and its response to mitogenic stimuli in glioma C6 cells. J Neurochem. 1997;68:898-908.
68. Gashler AL, Bonthron DT, Madden SL, Rauscher III FJ, Collins T, Sukhatme VP. Human PDGF A chain is transcriptionally repressed by the Wilms' tumor suppressor WT1. Proc Natl Acad Sci USA. 1992;89:10984-10988.
69. Wang Z-Y, Deuel TF. An S1 nuclease-sensitive homopurine/nomopyrimidine domain in the PDGF A-chain promoter contains a novel binding site for the growth factor-inducible protein EGR-1. Biochem Biophys Res Commun. 1992;188:433-434.
70. Wang Z-Y, Madden SL, Deuel TF, Rauscher III FJ. The Wilms' tumor gene product, WT1, represses transcription of the PDGF A-chain gene. J Biol Chem. 1992;267: 21999-22002.
71. Wang Z-Y, Qiu Q-Q, Deuel TF. The Wilms' tumor gene product WT1 activates or suppresses transcription through separate functional domains. J Biol Chem. 1993; 268:9172-9175.
72. Wang Z-Y, Qiu Q-Q, Huang J, Gurrieri M, Deuel TF. Products of alternatively spliced transcripts of the Wilms' tumor suppressor gene, WT1, have altered DNA binding specificity and regulate transcription in different ways Oncogene. 1995;10:415-422.
73. Wang Z-Y, Qiu Q-Q, Gurrieri M, Huang J, Deuel TF. WT1, the Wilms' tumor suppressor gene product, represses transcription through an interactive nuclear protein. Oncogene. 1995;10:1243-1247.
74. Harrington MA, Kyonicek B, Song A, Xia XL, Fredericks WJ, Rauscher III FJ. Inhibition of CSF-1 promoter activity by the product of the Wilms' tumor locus. J Biol Chem. 1993;268:21271-21275.
75. Drummond IA, Madden SL, Rohwer-Nutter P, Bell GI, Sukhatme VP, Rauscher III FJ. Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1. Science. 1992;257:674-678.
76. Werner H, Shen-Orr Z, Rauscher III FJ, et al. Inhibition of cellular proliferation by the Wilms' tumor suppressor WT1 is associated with suppression of insulin-like growth factor I receptor gene expression. Mol Cell Biol. 1995;15: 3516-3522.
77. Khachigian LM, Williams AJ, Collins T. Interplay of Sp1 and Egr-1 in the proximal PDGF A-chain promoter in cultured vascular endothelial cells. J Biol Chem. 1995;270: 27679-27686.
78. Khachigian LM, Lindner B, Williams AJ, Collins T. Egr-1-Induced endothelial gene expression: a common theme in vascular injury. Science. 1996;271:1427-1431.
79. Kaetzel DM, Maul FS, Liu B, Bonthron D, Fenstermaker RA, Coyne DW. PDGF A-chain gene transcription is mediated by positive and negative regulatory regions in the promoter. Biochem J. 1994;301:321-327.
80. Bhandari B, Wenzel UO, Marra F, Abboud HE. A nuclear protein in mesangial cells that binds to the promoter region of the PDGF-A chain gene. Induction by TPA. J Biol Chem. 1995;270:5541-5548.
81. SRF causes the aberrant induction of cellular immediate early genes through CArG boxes. Genes Dev. 1992;6:2066-2076.
82. Sakamoto KM, Nimer SD, Rosenblatt JD, Gasson JC. HTLV-I, and HTLV-II tax trans-activate the human EGR-1 promoter through different cis-acting sequences. Oncogene. 1992;7:2125-2130.
83. Akagi T, Ono H, Shimotohno K. Characterization of T cells immortalized by Taxi of human T-cell leukemia virus type 1. Blood. 1995;86:4243-4249.
84. Yoo YD, Eda H, Park K, et al. Regulation of transforming growth factor-beta 1 expression by the hepatitis B virus (HBV) X transactivator. Role in HBV pathogenesis. J Clin Invest. 1996;97:388-395.
85. Calogero A, Cuomo L, D'Onofrio M, et al. Expression of EGR-1 correlation with the transformed phenotype and the type of viral latency in EBV genome positive lymphoid cell lines. Oncogene. 1996;13:2105-2112.
86. Kageyama R, Merlino GT, Pastan I. Epidermal growth factor (EGF) receptor gene transcription: requirement for Sp1 and an EGF receptor-specific factor. J Biol Chem. 1988;263:6326-6329.
87. Chen X, Azizkhan JC, Lee DC. The binding of transcription factor Sp1 to multiple sites is required for maximal expression from the rat transforming growth factor α promoter Oncogene. 1992;7:1805-1815.
88. Chen X, Wright KL, Berkowitz EA, Azizkhan JC, Ting J P-Y, Lee DC. Protein interactions at Sp-1 like sites in the TGF a promoter as visualized by in vivo genomic footprinting. Oncogene. 1994;9:3179-3187.
89. Geiser AG, Kim SJ, Roberts AB, Sporn MB. Characterization of the mouse transforming growth factor-beta 1 promoter and activation by the Ha-ras oncogene. Mol Cell Biol. 1991;11:84-92.
90. Werner H, Re GG, Drummond IA, et al. Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product. Proc Natl Acad Sci USA. 1993;90: 5828-5832.
91. Hofmann W, Royer H-D, Drechsler M, Schneider S, Royer-Pokora B. Characterization of the transcriptional regulatory region of the human WT1 gene. Oncogene. 1993;8:3123-3132.
92. Ackerman SL, Minder AG, Williams GT, Bobonis C, Yeung C-Y. Functional significance of an overlapping consensus binding motif for Sp1 and Zif268 in the murine adenosine deaminase gene promoter. Proc Natl Acad Sci USA. 1991;88:7523-7527.
93. Li Y, Camp S, Rachinsky TL, Bongiorno C, Taylor P. Promoter element and transcriptional control of the mouse acetylcholinesterase gene. J Biol Chem. 1993;268: 3563-3572.
94. Mutero A, Camp S, Taylor P. Promoter element of the mouse acetylcholinesterase gene transcriptional regulation during muscle differentiation. J Biol Chem. 1995;270: 1866-1872.
95. Englert C, Hou X, Maheswaran S, Bennett P, Ngwu C, Garvin AJ, Rosner MR, Haber DA. WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis. EMBO J. 1995;14:4662-4675.
96. Ebert SN, Wong DL. Differential activation of the rat phenylethanolamine N-methyltransferase gene by Sp1 and Egr-1. J. Biol Chem. 1995;270:17299-17305.
97. Shingu T, Bornstein P. Overlapping Egr-1 and Sp1 sites function in the regulation of transcription of the mouse thrombospondin 1 gene. J Biol Chem. 1994;269:32551-32557.
98. Kilbourne EJ, Widom R, Harnish DC, Malik S, Karathanasis SK. Involvement of early growth response factor Egr-1 in apolipoprotein AI gene transcription. J Biol Chem. 1995;270:7004-7010.
99. Kramer B, Meichle A, Hensel G, Charnay P, Kronke M. Characterization of an krox-24/Egr-1-responsive element in the human tumor necrosis factor promoter. Biochim Biophys Acta. 1994;1219:413-421.
100. Cui M-Z, Parry GCN, Oeth P, et al. Transcriptional regulation of the tissue factor gene in human epithelial cells is mediated by Sp1 and EGR-1. J Biol Chem. 1996;271:2731-2739.
101. Huang R-P, Fan Y, De Belle I, et al. Decreased Egr-1 expression in human, mouse and rat mammary cells and tissues correlates with tumor formation. Int J Cancer. 1997;72:102-109.
102. Huang R-P, Darland T, Okumura D, Mercola D, Adamson E. Suppression of v-sis-dependent transformation by the transcription factor, EGR.-1. Oncogene. 1994;9:1367-1377.
103. Huang R-P, Liu C-T, Fan Y, Mercola D, Adamson ED. EGR-1 Negatively Regulates Human tumor Cell Growth via the DNA-Binding Domain. Cancer Res. 1995;55: 5054-5062.
104. Kieser A, Seitz T, Adler HS, et al. Protein Kinase C-zeta reverts v-raf transformation of NIH-3T3 cells. Genes Dev. 1996;10:1455-1466.
105. Powell CT, Gschwend JE, Fair WR, Brittis NJ, Stec D, Huryk R. Overexpression of protein kinase C-zeta (PKC-zeta) inhibits invasive and metastatic abilities of Dunning R-3327 MAT-LyLu rat prostate cancer cells. Cancer Res. 1996;56:4137-4141.
106. Fundia A, Gorla N, Larripa I. Non-random distribution of spontaneous chromosome aberrations in two Bloom Syndrome patients. Hereditas. 1995;122:239-43.
107. Goguel AF, Fouquet F, Duverger A, et al. Evolution of chromosomal alterations and biologic features in two small cell lung carcinoma cell lines established from one patient during the course of the disease. Cancer Genet Cytogenet. 1995;80:47-54.
108. Levin WJ, Baynor RB, Press MG, Sukhatme V, Slamon DJ. Differential expression of immediate early transcription factors in human lung. J Cell Biochem. 1992;16B: 240A.
109. Levin WJ, Press MF, Gaynor RB, et al. Expression patterns of immediate early transcription factors in human non-small cell lung cancer. Oncogene. 1995;11:1261-1269.
110. Le Beau MM, Espinosa III R, Neuman WL, et al. Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. Proc Natl Acad Sci USA. 1993;90:5484-5488.
111. Horrigan SK, Westbrook CA, Kirn AH, Banerjee M, Stock W, Larson RA. Polymerase chain reaction-based diagnosis of del (5q) in acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval. Blood. 1996;88:2665-2670.
112. Boulrwood J, Fidler C, Lewis S, et al. Molecular mapping of uncharacteristically small 5q deletions in two patients with the 5q- syndrome: delineation of the critical region on 5q and identification of a 5q- breakpoint. Genomics. 1994;19:425-4232.
113. Nagarajan L, Zavadil J, Claxton D, et al. Consistent loss of the D5S89 locus mapping telomeric to the interleukin gene cluster and centromeric to EGR-1 in patients with 5q- chromosome. Blood. 1994;83:199-208.
114. Sager R, Sheng S, Pemberton P, Hendrix M. Maspin: a tumor suppressing serpin. Curr Top Microbiol Immunol. 1996;213:51-64.
115. Mohiuddin M, Ahmed MM, Venkatasubbarao K, Fruitwala S, Rangnekar V, Cross P, Weinstein M. EGR1 expression and mutation analysis in prostate tumors. Proc Am Assoc Cancer Res. 1997;38:427.
116. Kuranami M, Powell CT, Hug H, Zeng Z, Cohen AM, Guillem JG. Differential expression of protein kinase C isoforms in human colorectal cancers. J Surg Res. 1995; 58:233-9.
117. Mercola DA, Carpenter P, Grover-Bardwick A, and Mercola M. Rapid, Complete, and Reversible Transformation by v-sis precedes irreversible transformation. On-cogene. 1992;7:1793-1803.
118. Takeuchi Y, Fukumoto S, Matsumoto T. Relationship between actions of TGF-beta and cell surface expression of its receptors in clonal osteoblastic cells. J Cell Physiol. 1995;162:315-321.
119. Yamada N, Kato M, Yamashita H, Nister M, Miyazono K, Heldin CH, Funa K. Enhanced expression of TGF-β and its type-I and type-II receptors in human glioblastoma. Int J Cancer. 1995;62:386-392.
120. Kalkhoven E, Roelen BA, de Winter JP, Mummery CL, van den Eijnden-van Raaij AJ, van der Saag PT, van der Burg B. Resistance to TGF-β, and activin due to reduced receptor expression in human breast tumor cell lines. Cell Growth Differ. 1995;6:1151-1161.
121. Arteaga CL, Tandon AK, Von Hoff DD, Osborne CK. TGF-β: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells. Cancer Res. 1988;48:3898.
122. Dey BR, Sukhatme VP, Roberts AB, Sporn MB, Rauscher III FJ, Kim S-J. Repression of the TGF-β 1 gene by the Wilms' tumor suppressor WT1 gene product. Mol Endocrinol 1994;8:595-602.
123. Liu C, Adamson ED, Calagero A, Ragona G, Mercola D. EGR-1, the Reluctant Suppressor. Crit Rev Oncog. 1996; 7:101-125.
124. Liu C, Adamson ED, Mercola D. The Transcription Factor EGR-1 Suppresses the Growth and Transformation of HT-1080 Fibrosarcoma Cells by Induction of Transforming Growth Factor β-1. Proc Natl Acad Sci USA. 93:1996;11831-11836.
125. Danielpour D, Dart LL, Flanders KC, Roberts AB, Sporn MB. Immunodetection and quantitation of the two forms of TGF-β (-β 1 and -β 2) secreted by cells in culture. J Cell Physiol. 1989;138:79-86.
126. Kim SJ, Park K, Rudkin BB, Dey BR, Sporn MB, Roberts AB. Nerve growth factor induces transcription of transformation growth factor-beta 1 through a specific promoter element in PC12 cells. J Biol Chem. 1994;269: 3739-3744.
127. Sharma HS, van Heugten HA, Goedbloed MA, Verdouw PD, Lamers JM. Angiotensin II induced expression of transcription factors precedes increase in transforming growth factor-beta 1 mRNA in neonatal cardiac fibroblasts. Biochem Biophys Res Commun. 1994;205:105-112.
128. Attisano L, Wrana JL, Lopez-Casillas F, Massague J. TGF-β receptors and actions. Biochim Biophys Acta. 1994;1222:71-80.
129. Roberts AB, Sporn MB. Physiological actions and clinical application of TGF-β. Growth Factors. 1993;8:1-9.
130. Battegay EJ, Raines EW, Seifert RA, Bowen-Pope DF, Ross R. TGF-β induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell. 1990;63:515-524.
131. Alexandrow MG, Moses HL. TGF-β and cell cycle regulation. Cancer Res. 1995;55:1452-1457.
132. Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals Cell. 1994;78:59-66.
133. Ewen ME, Sluss HK, Whitehouse LL, Livington DM. TGF-β inhibition of cdk4 synthesis is linked to cell cycle arrest. Cell. 1993;73:487-497.
134. Eblen ST, Fautsch MP, Burnette RJ, Joshi P, Leof EB. Cell cycle-dependent inhibition of p34cdc2 synthesis by TGF β 1 in cycling epithelial cells. Cell Growth Differ. 1994;5:109-116.
135. 1/S-phase growth arrest. Mol Cell Biol. 1991;11:1185-1194.
136. Kip1, a cyclin-cdk inhibitor, links TGF-β and contact inhibition to cell cycle arrest. Genes Dev. 1994;8:9-22.
137. INK4B through an Sp1 consensus site. J Biol Chem. 1995;270:26750-26753.
138. Datto MB, Yu Y, Wang XF. Functional analysis of the TGF-β responsive elements in the WAF1/Cip1/p21 promoter. J Biol Chem. 1995;270:28623-28628.
139. INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature. 1994;371:257-261.
140. Kip2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev. 1995;9:639-649.
141. Fang F, Orend G, Watanabe N, Hunter T, Ruoslahti E. Dependence of cyclin E-CDK2 kinase activity on cell anchorage. Science. 1996;271:499-502.
142. Paulsson Y, Karlsson C, Heldin CH, Westermark B. Density-dependent inhibitory effect of TGF-β 1 on human fibroblasts involves the down-regulation of PDGF alpha-receptors. J. Cell Physiol. 1993;57:97-103.
143. Majack RA, Majesky MW, Goodman LV. Role of PDGF-A expression in the control of vascular smooth muscle cell growth by TGF-β. J Cell Biol. 1990;111:239-247.
144. Kim IY, Ahn H-J, Zelner DJ, et al. Genetic change in TGF-β receptor type I gene correlates with insensitivity to TGF-β1 in human prostate cancer cells. Cancer Res. 1996;56:44-48.
145. Seifert RA, Coats SA, Raines EW, Ross R, Bowen-Pope DF. PDGF receptor alpha-subunit mutant and reconstituted cell lines demonstrate that TGF-β can be mitogenic through PDGF A-chain-dependent and -independent pathways. J Biol Chem. 1994;269:13951-13955.
146. Stouffer GA, Owens GK. TGF-β promotes proliferation of cultured SMC via both PDGF-AA-dependent and PDGF-AA-independent mechanisms. J Clin Invest. 1994; 93:2048-2055.
147. Testa U, Masciulli R, Tritarelli E, et al. Transforming growth factor-beta potentiates vitamin DS-induced terminal monocytic differentiation of human leukemic cell lines. J Immunol. 1993;150:2418-2430.
148. Hamon G, Mulloy RH, Chen G, Chow R, Birkenmaier C, Horn JK. Transforming growth factor-beta 1 lowers the CD14 content of monocytes. J Surg Res. 1994;57:574-578.
149. Huang R-P, Fan Y, Mercola D, Adamson E. Reciprocal Modulation between Sp1 and Egr-1. J Cell Biochem. 1997;66:1-11.
150. Murohashi I, Endho K, Nishida S, et al. Differential effects of TGF-beta 1 on normal and leukemic human hematopoietic cell proliferation. Exp Hematol. 1995;23: 970-977.
151. Larocca LM, Teofili L, Sica S, et al. Quercetin inhibits the growth of leukemic progenitors and induces the expression of transforming growth factor-beta 1 in these cells. Blood. 1995;85:3654-3661.
152. Taetle R, Payne C, Dos Santos B, Russell M, Segarini P. Effects of transforming growth factor beta 1 on growth and apoptosis of human acute myelogenous leukemia cells. Cancer Res. 1993;53:3386-3393.
153. Masuya M, Kita K, Shimizu N, et al. Biologic characteristics of acute leukemia after myelodysplastic syndrome. Blood. 1993;81:3388-3394.
154. Kulkarni AB, Ward JM, Yaswen L, et al. Transforming growth factor-beta 1 null mice. An animal model for inflammatory disorders. Am J Pathol. 1995;146:264-275.
155. Boivin GP, O'Toole BA, Orsmby IE, et al. Onset and progression of pathological lesions in transforming growth factor-beta 1-deficient mice. Am J Pathol. 1995; 146:276-88.
156. Chiu R, Angel P, Karin M. Jun-B differs in its biological properties and is a negative regulator of, c-jun. Cell. 1989;59:979-986.
157. Schutte J, Viallet J, Nau M, Segal S, Fedorko J, Minna J. jun-B inhibits and c-fos stimulates the transforming and trans-activating activities of c-jun. Cell. 1989;59:987-997.
158. Mauviel A, Chung KY, Agarwal A, Tamai K, Uitto J. Cell-specific induction of distinct oncogenes of the Jun family is responsible for differential regulation of collagenase gene expression by transforming growth factor-beta in fibroblasts and keratinocytes. J Biol Chem. 1996; 271:10917-10923.
159. Subramaniam M, Oursler MJ, Rasmussen K, Riggs BL, Spelsberg TC. TGF-beta regulation of nuclear proto-oncogenes and TGF-beta gene expression in normal human osteoblast-like cells. J Cell Biochem. 1995;57:52-61.
160. Beauchamp RD, Sheng HM, Ishizuka J, Townsend CM Jr, Thompson JC. Transforming growth factor (TGF)-beta stimulates hepatic jun-B and fos-B proto-oncogenes and decreases albumin mRNA. Ann Surg. 1992;216:300-307 (discussion, 307-308).
161. Fynan TM, Reiss M. Resistance to inhibition of cell growth by TGF-β and its role in oncogenesis. Crit Rev Oncog. 1993;4:493-540.
162. Markowitz S, Wang J, Myeroff L, et al. Inactivation of the type II TGF-β receptor colon cancer cells with microsatellite instability. Science. 1996;268:1336-1338.
163. Park K, Kim S-J, Bang Y-J, et al. Genetic changes in the TGF β (TGF-β) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-β. Proc Natl Acad Sci USA. 1994;91:8772-8776.
164. Hahn SA, Schutte M, Hoque SAT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science. 1996;271:350-353.
165. Kim IY, Ahn H-J, Zelner DJ, et al. Genetic change in TGFβ receptor type I gene correlates with insensitivity to TGF-β1 in human prostate cancer cells. Cancer Res. 1996;56:44-48.
166. Kalkhoven E, Beraldi E, Panno ML, De Winter JP, Thijssen HH, Van der Burg B. Growth inhibition by anti-estrogens and progestins in TGF-β-resistant and -sensitive breasttumor cells. Int J Cancer. 1996;65:682-687.
167. Sun L, Wu G, Willson JK, Zborowska E, Yang J, Rajkarunanayake I, Wang J, Gentry LE, Wang XF, Brattain MG. Expression of TGF β type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. J Biol Chem. 1994;269:26449-26455.
168. Wang J, Sun L, Myeroff L, et al. Demonstration that mutation of the type IITGF β receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells. J Biol Chem. 1995;270:22044-22049.
169. Ahmed MM, Venkatasubbarao K, Fruitwala SM, et al. EGR-1 induction is required for maximal radiosensitivity in A375-C6 melanoma cells. J Biol Chem. 1996;271: 29231-29237.
170. Nair PN, Muthukkumar S, Sells SF, et al. Early growth response-1 dependent apoptosis is mediated by p53. J Biol Chem. 1997;272:20131-20138.
171. Lane DP. p53, guardian of the genome. Nature. 1992;358: 15-16.
172. Ahmed MM, Sells SF, Venkatasubbarao K, Fruitwala SM, Muthukkumar S, Manning S, Mohiuddin M, Rangnekar VM. Ionizing radiation-inducible apoptosis in the absence of p53 linked to transcription factor EGR-1. J Biol Chem. 1997;272:33056-33061.
173. Preston GA, Lyon TT, Yin Y, et al. Induction of apoptosis by c-fos protein. Mol Cell Biol. 1996;16:211-218.
174. Hemerking H, Eick D. Mediation of c-myc-induced apoptosis by p53. Science. 1994;265:2091-2093.
175. Wagner AJ, Kokontis JM, Hay N. Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21/waf1/cip1. Genes Dev. 1994;8:2817-2830.
176. Sells SF, Muthukumar S, Sukhatme, et al. The zinc-finger transcription factor EGR-1 impedes interleukin-1-inducible tumor growth arrest. Mol Cell Biol. 1995;15:682-692.
177. Masumi A, Akamatsu Y, Kitagawa T. Modulation of the synthesis and glycosylation of the glucose transporter protein by transforming growth factor - β1 in swiss 3T3 fibroblasts. Biochim Biophys Acta. 1993; 1145: 227-234.